Enrich Therapeutics was selected for the inaugural BioTools Innovator 2021 Accelerator!

Branford, CT August 1, 2021 / BioTools Innovator, a new program run by MedTech Innovator, with a focus on accelerating life science tools and diagnostics, just announced the ten companies selected to participate in the organization’s inaugural three-month virtual mentorship-focused Accelerator program.

BioTools Innovator works closely with stakeholders across the industry to foster the growth of early to mid-stage startups. The top ten leading-edge biotechnology startups are developing solutions for cell research, genomics, data and informatics, and synthetic biology and hail from across the U.S. and Europe.

Enrich Therapeutics Inc. is honored to be chosen by BioTools Innovator as one of the top 10 leading biotech startups developing solutions to advance research & improve human health! The company looks forward to participating in the inaugural 2021 Accelerator program.

About Enrich Therapeutics Inc.:
Enrich Therapeutics is a privately held company, founded in July 2018, focused on the development of a novel single-cell isolation platform along with critical life science applications. Enrich Therapeutics aims to enhance global biomedical research at a true single-cell level with superior affordability and strength. Its static cell capture technology enables clone isolation under the desired micro-environment with real-time monitoring. Enrich technology is making an extensive impact in the fields of basic biology, CAR-T, antibody, tumor genetics, etc., and is committed to isolating single clones from any physiologically relevant scenario. Additional information about the company may be found at www.enrichtx.com.

For more information:

Investor Contact:
investors@enrichtx.com

General Contact:
inquiry@enrichtx.com